Explore our latest content

Biopharma Dealmakers brings together life sciences companies and individuals looking to identify and attract partners and dealmaking opportunities.

Advertisement

  • Better data for better insights and improved outcomes—Molecular Health has built one of the largest, deepest and fully curated digital platforms for biomedicine in the world. The company’s ‘Dataome’ provides the foundation for actionable insights for stakeholders across the healthcare ecosystem.

    • Molecular Health GmbH
    Advertisement Feature
  • Auransa’s AI-driven prediction of drug candidates and corresponding patient responders increases the chances of clinical trial success.

    • Auransa Inc.
    Advertisement Feature
  • Deep Quartet, a drug discovery platform developed by INTAGE Healthcare and the Institute for Theoretical Medicine (ITM) uses AI technologies to design new lead compound structures based on pharmacophore models.

    • INTAGE Healthcare
    Advertisement Feature
  • Our monthly roundup of 'business of science' stories from across Springer Nature’s portfolio of journals explores the relationships between academia, startups and big pharma, as well as following the progress of the COVID-19 vaccine rollout.

    • Raveena Bhambra
    News Feature
  • Vincerx applies a modular approach in the development of antibody–drug conjugates by incorporating novel targeting and safety features. The company’s lead compounds exhibit high efficacies with minimal toxicities that are expected to improve therapeutic windows. Vincerx believes that partners with first-in-class antibodies, clinical stage antibodies or ADCs against promising targets will benefit from Vincerx’s next-generation payload-linker technologies.

    • Vincerx Pharma
    Advertisement Feature
  • Gene therapy company FerGene Inc. is developing products for the treatment of urologic cancers, the company’s lead product, nadofaragene firadenovec, uses a non-replicating adenovirus vector to deliver the gene for interferon alfa-2b into bladder cells for the treatment of bladder cancer.

    • FerGene Inc.
    Advertisement Feature
  • With its plug-and-play cell therapy platform and complementary bispecific NK cell engagers, Cytovia aims to create both single and combination therapies for cancer treatment.

    • Cytovia Therapeutics
    Advertisement Feature